Cite
HARVARD Citation
Alvarez‐Larrán, A. et al. (2022). Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer. 128 (13), pp. 2441-2448. [Online].